More articles from Article

Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
Masaaki Komatsu, Keiko Hiyama, Keiji Tanimoto, Mayu Yunokawa, Keiko Otani, Megu Ohtaki, Eiso Hiyama, Junzo Kigawa, Michitaka Ohwada, Mitsuaki Suzuki, Nobutaka Nagai, Yoshiki Kudo, Masahiko Nishiyama

Molecular Cancer Therapeutics Mar 2006, 5 (3) 767-775; DOI: 10.1158/1535-7163.MCT-05-0408
Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
Elvira Crescenzi, Angela Chiaviello, Gianfranco Canti, Elena Reddi, Bianca Maria Veneziani, Giuseppe Palumbo

Molecular Cancer Therapeutics Mar 2006, 5 (3) 776-785; DOI: 10.1158/1535-7163.MCT-05-0425
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Ruoping Tang, Anne-Marie Faussat, Patricia Majdak, Christophe Marzac, Sabine Dubrulle, Zora Marjanovic, Ollivier Legrand, Jean-Pierre Marie

Molecular Cancer Therapeutics Mar 2006, 5 (3) 723-731; DOI: 10.1158/1535-7163.MCT-05-0164
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O⁶-benzylguanine
Tomio Ueno, Sae Hee Ko, Elizabeth Grubbs, Yasunori Yoshimoto, Christi Augustine, Zeinab Abdel-Wahab, Tsung-Yen Cheng, Omar I. Abdel-Wahab, Scott K. Pruitt, Henry S. Friedman, Douglas S. Tyler

Molecular Cancer Therapeutics Mar 2006, 5 (3) 732-738; DOI: 10.1158/1535-7163.MCT-05-0098
Identification of a small topoisomerase I–binding peptide that has synergistic antitumor activity with 9-aminocamptothecin
Christopher D. Pond, Kathryn M. Marshall, Louis R. Barrows

Molecular Cancer Therapeutics Mar 2006, 5 (3) 739-745; DOI: 10.1158/1535-7163.MCT-05-0377
Sulindac independently modulates extracellular signal–regulated kinase 1/2 and cyclic GMP–dependent protein kinase signaling pathways
Pamela L. Rice, Stevany L. Peters, K. Scott Beard, Dennis J. Ahnen

Molecular Cancer Therapeutics Mar 2006, 5 (3) 746-754; DOI: 10.1158/1535-7163.MCT-05-0210
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses
Svetlana Komarova, Yosuke Kawakami, Mariam A. Stoff-Khalili, David T. Curiel, Larisa Pereboeva

Molecular Cancer Therapeutics Mar 2006, 5 (3) 755-766; DOI: 10.1158/1535-7163.MCT-05-0334
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase
Garth Powis, Peter Wipf, Stephen M. Lynch, Anne Birmingham, D. Lynn Kirkpatrick

Molecular Cancer Therapeutics Mar 2006, 5 (3) 630-636; DOI: 10.1158/1535-7163.MCT-05-0487
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
Dimpy Koul, Ruijun Shen, Sherry Bergh, Xiaoyang Sheng, Shishir Shishodia, Tiffany A. Lafortune, Yiling Lu, John F. de Groot, Gordon B. Mills, W.K. Alfred Yung

Molecular Cancer Therapeutics Mar 2006, 5 (3) 637-644; DOI: 10.1158/1535-7163.MCT-05-0453
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells
Lincoln A. Edwards, Maite Verreault, Brian Thiessen, Wieslawa H. Dragowska, Yanping Hu, Juliana H.F. Yeung, Shoukat Dedhar, Marcel B. Bally

Molecular Cancer Therapeutics Mar 2006, 5 (3) 645-654; DOI: 10.1158/1535-7163.MCT-05-0099

Main menu

User menu

Search

More articles from Article

Pages

Articles

Info for

About MCT